Kenvue (KVUE) Projected to Post Earnings on Thursday

Kenvue (NYSE:KVUE) is expected to be releasing its Q4 2025 results before the market opens on Thursday, February 5th. Analysts expect Kenvue to post earnings of $0.22 per share for the quarter. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, February 6, 2026 at 12:30 PM ET.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The company had revenue of $3.76 billion for the quarter, compared to the consensus estimate of $3.83 billion. During the same quarter in the prior year, the business posted $0.28 EPS. The firm’s quarterly revenue was down 3.5% compared to the same quarter last year. On average, analysts expect Kenvue to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Kenvue Stock Down 0.8%

KVUE stock opened at $17.36 on Thursday. The business has a 50 day moving average of $17.13 and a 200 day moving average of $18.08. The firm has a market cap of $33.25 billion, a PE ratio of 23.14 and a beta of 0.60. Kenvue has a twelve month low of $14.02 and a twelve month high of $25.17. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66.

Kenvue Dividend Announcement

The business also recently declared a dividend, which will be paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th will be issued a dividend of $0.2075 per share. The ex-dividend date is Wednesday, February 11th. Kenvue’s dividend payout ratio (DPR) is presently 110.67%.

Insider Activity at Kenvue

In other news, Director Jeffrey C. Smith acquired 3,200,000 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The stock was bought at an average price of $17.37 per share, with a total value of $55,584,000.00. Following the completion of the acquisition, the director directly owned 27,307,632 shares of the company’s stock, valued at approximately $474,333,567.84. The trade was a 13.27% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.17% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Advisory Services Network LLC raised its stake in Kenvue by 2.0% during the 2nd quarter. Advisory Services Network LLC now owns 49,807 shares of the company’s stock worth $1,068,000 after acquiring an additional 983 shares during the period. CIBC Private Wealth Group LLC increased its stake in shares of Kenvue by 20.1% in the third quarter. CIBC Private Wealth Group LLC now owns 6,388 shares of the company’s stock worth $104,000 after purchasing an additional 1,068 shares in the last quarter. Port Capital LLC raised its position in shares of Kenvue by 10.6% during the 3rd quarter. Port Capital LLC now owns 15,994 shares of the company’s stock valued at $260,000 after purchasing an additional 1,537 shares during the period. Hayek Kallen Investment Management lifted its stake in shares of Kenvue by 8.6% during the 2nd quarter. Hayek Kallen Investment Management now owns 32,910 shares of the company’s stock valued at $689,000 after buying an additional 2,610 shares in the last quarter. Finally, Johnson Financial Group Inc. lifted its stake in shares of Kenvue by 277.8% during the 3rd quarter. Johnson Financial Group Inc. now owns 5,062 shares of the company’s stock valued at $82,000 after buying an additional 3,722 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on KVUE shares. Canaccord Genuity Group reiterated a “hold” rating and issued a $15.00 price target (down previously from $26.00) on shares of Kenvue in a research note on Wednesday, October 29th. Citigroup decreased their target price on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a report on Thursday, October 9th. Barclays upped their target price on shares of Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Monday, November 10th. UBS Group reduced their price target on shares of Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a research report on Wednesday, October 8th. Finally, Evercore ISI set a $18.00 price objective on Kenvue in a research report on Tuesday, October 28th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and twelve have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $20.23.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.